Thyrotropin-releasing hormone (TRH) is a peptide hormone released from hypothalamic tissue and stimulates the release of thyroid-stimulating hormone (thyrotropin) from the mammalian anterior pituitary by binding to the TRH receptor on the cell surface of the pituitary.1,2) TRH is a tripeptide with the amino acid sequence L-pyroglutamyl-L-histidyl-L-prorineamide (L-pGlu-His-Pro-NH 2 ). The wide distribution of TRH throughout the central nervous system and the findings of various biochemical, pharmacological and behavioral studies strongly suggest that TRH likely acts as a neuromodulator/neurotransmitter in extrahypothalamic brain areas.
2,3)Current evidence strongly indicates that pyroglutamyl aminopeptidase II EC 3.4.19.6) is the principal enzyme responsible for terminating the actions of neuronally released TRH by removing the L-pGlu residue.4-6) PAP-II is a membrane-anchored zinc-metalloenzyme primarily located in the central nervous system and is known as a highly specific enzyme for TRH and very closely related compounds.
1,7)Pyroglutamyl aminopeptidase I (PAP-I, EC 3.4.19.3), a typical cytosolic cysteine peptidase, also can hydrolyze TRH as well as bioactive neuropeptides such as luliberin (LH-RH) and neurotensin due to its broad substrate specificity. [8][9][10] But the cytosolic peptidases are generally considered to have no role in the metabolism of these bioactive peptides, because neuropeptides are commonly hydrolyzed by ectoenzymes localized on the membrane of cells with the active site facing the extracellular space or by lysosomal peptidases after endocytosis.1,11) Nevertheless, the contribution of cytosolic PAP-I to the hydrolysis of TRH in vivo is controversial. Charli et al. 6) reported that pGlu diazomethyl ketone, a PAP-I inhibitor, did not enhance TRH levels in the brain in vivo or in vitro, but Faivre-Bauman et al. 12) observed increased levels of TRH when primary cultures of hypothalamic cells were treated with Z-Gly-ProCHN 2 , also known as a PAP-I inhibitor.Recently we expressed the functional forms of rat, mouse and human PAP-Is by Escherichia coli as a single protein and obtained an antibody raised against rat recombinant PAP-I.
13)Using these preparations, we showed that L-pGlu p-nitroanilide (L-pGlu-pNA) is a good non-peptide synthetic substrate for recombinant PAP-Is and is hydrolyzed solely by cytosolic PAP-I from the immunoprecipitation study using the antibody.13) We also demonstrated that the liver and kidney show relatively high PAP-I activities compared with other tissues tested.13) More recently we found that PAP-I is involved in the hydrolysis of some xenobiotic compounds having an LpGlu or L-pGlu-related structure, now under development in our company. 14,15) In this study, by using the recombinant PAP-Is and the antibody against rat PAP-I, we investigated the possible contribution of PAP-I to the degradation of TRH in rats based on biochemical experiments in brain subcellular fractions and immunohistochemical localization of PAP-I in the brain as well as the liver and kid...